NASDAQ: PTGX

Protagonist Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) resulting from allegations that Protagonist Therapeutics may have issued materially misleading business information to the investing public.

If you purchased Protagonist Therapeutics securities and would like to join the prospective action, please click “Join This Class Action.”

Retainer Agreement
See Full Details
Join This Class Action
If you purchased Protagonist Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On April 13, 2022, after market hours, Protagonist Therapeutics disclosed in a filing with the U.S. Securities and Exchange Commission that “[t]he Company has received a letter from United States Food and Drug Administration (the “FDA”) indicating the FDA’s intent to rescind Breakthrough Therapy Designation for the Company’s rusfertide product candidate in polycythemia vera,” citing “observed malignancies[.]”

On this news, Protagonist’s stock price fell $5.57 per share, or 21%, to close at $19.95 per share on April 14, 2022.

Follow us on:
Twitter
Company Name: Protagonist Therapeutics, Inc.
Stock Symbol: PTGX
Class Period: N/A
Court: N/A
Share This Class Action
Join This Class Action

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Case Attorneys

Phillip Kim

New York, Philadelphia Metro

275 Madison Avenue
40th Floor
New York, NY 10016

Tel: (212) 686-1060
Privacy Policy | Accessibility
Scroll to Top